Brokerages expect that ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) will announce earnings of ($0.34) per share for the current quarter, Zacks reports. Zero analysts have made estimates for ASLAN PHARMACEUTICALS ADR REP 5’s earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.30). The business is scheduled to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that ASLAN PHARMACEUTICALS ADR REP 5 will report full-year earnings of ($1.34) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($1.30). For the next fiscal year, analysts forecast that the business will report earnings of ($1.48) per share, with EPS estimates ranging from ($1.81) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover ASLAN PHARMACEUTICALS ADR REP 5.
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last posted its quarterly earnings data on Monday, August 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06).
ASLN traded down $0.10 on Monday, hitting $7.30. 937 shares of the company’s stock traded hands, compared to its average volume of 3,874. ASLAN PHARMACEUTICALS ADR REP 5 has a one year low of $5.08 and a one year high of $10.44.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. MYDA Advisors LLC bought a new stake in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter valued at approximately $195,000. Platinum Investment Management Ltd. bought a new stake in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter valued at approximately $2,532,000. Finally, Temasek Holdings Private Ltd bought a new stake in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter valued at approximately $12,660,000. 10.93% of the stock is currently owned by institutional investors.
About ASLAN PHARMACEUTICALS ADR REP 5
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors.
Read More: What is the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.